Huaitian Liu
YOU?
Author Swipe
View article: Molecular, metabolic, and histological subtypes of pancreatic ductal adenocarcinoma and its tumor microenvironment: Insights into tumor heterogeneity and clinical implications
Molecular, metabolic, and histological subtypes of pancreatic ductal adenocarcinoma and its tumor microenvironment: Insights into tumor heterogeneity and clinical implications Open
Pancreatic ductal adenocarcinoma (PDAC) is a highly heterogeneous cancer with poor prognosis and limited therapeutic options. Bulk transcriptomic profiling has identified two major gene expression-based molecular subtypes: classical/progen…
View article: <scp>ELAPOR1</scp> induces the classical/progenitor subtype and contributes to reduced disease aggressiveness through metabolic reprogramming in pancreatic cancer
<span>ELAPOR1</span> induces the classical/progenitor subtype and contributes to reduced disease aggressiveness through metabolic reprogramming in pancreatic cancer Open
Pancreatic ductal adenocarcinoma (PDAC) is a heterogeneous disease with distinct molecular subtypes described as classical/progenitor and basal‐like/squamous PDAC. We hypothesized that integrative transcriptome and metabolome approaches ca…
View article: ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer
ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer Open
Pancreatic ductal adenocarcinoma (PDAC) manifests diverse molecular subtypes, including the classical/progenitor and basal-like/squamous subtypes, with the latter known for its aggressiveness. We employed integrative transcriptome and meta…
View article: LMO3 is a suppressor of the basal-like/squamous subtype and reduces disease aggressiveness of pancreatic cancer through glycerol 3-phosphate metabolism
LMO3 is a suppressor of the basal-like/squamous subtype and reduces disease aggressiveness of pancreatic cancer through glycerol 3-phosphate metabolism Open
Pancreatic ductal adenocarcinoma (PDAC) encompasses diverse molecular subtypes, including the classical/progenitor and basal-like/squamous subtypes, each exhibiting distinct characteristics, with the latter known for its aggressiveness. We…
View article: Loss of NAT10 disrupts enhancer organization via p300 mislocalization and suppresses transcription of genes necessary for metastasis progression
Loss of NAT10 disrupts enhancer organization via p300 mislocalization and suppresses transcription of genes necessary for metastasis progression Open
Acetylation of protein and RNA represent a critical event for development and cancer progression. NAT10 is the only known RNA acetylase that catalyzes the N4-actylcytidine (ac4C) modification of RNAs. Here, we show that the loss of NAT10 s…
View article: SERPINB3-MYC axis induces the basal-like/squamous subtype and enhances disease progression in pancreatic cancer
SERPINB3-MYC axis induces the basal-like/squamous subtype and enhances disease progression in pancreatic cancer Open
View article: LMO3 is a suppressor of the basal-like/squamous PDAC subtype and reduces disease aggressiveness of pancreatic cancer through glycerol 3-phosphate metabolism
LMO3 is a suppressor of the basal-like/squamous PDAC subtype and reduces disease aggressiveness of pancreatic cancer through glycerol 3-phosphate metabolism Open
Pancreatic ductal adenocarcinoma (PDAC) encompasses diverse molecular subtypes, including the classical/progenitor and basal-like/squamous subtypes, each exhibiting distinct characteristics, with the latter known for its aggressiveness. We…
View article: Diabetes-associated breast cancer is molecularly distinct and shows a DNA damage repair deficiency
Diabetes-associated breast cancer is molecularly distinct and shows a DNA damage repair deficiency Open
Diabetes commonly affects patients with cancer. We investigated the influence of diabetes on breast cancer biology using a 3-pronged approach that included analysis of orthotopic human tumor xenografts, patient tumors, and breast cancer ce…
View article: ELAPOR1 induces the classical/progenitor subtype and contributes to reduced disease aggressiveness through metabolic reprogramming in pancreatic cancer
ELAPOR1 induces the classical/progenitor subtype and contributes to reduced disease aggressiveness through metabolic reprogramming in pancreatic cancer Open
Pancreatic ductal adenocarcinoma (PDAC) is a heterogeneous disease with distinct molecular subtypes classified as classical/progenitor and basal-like/squamous. We hypothesized that integrative transcriptomic and metabolomic approaches can …
View article: Noncoding RNA circuitry in melanoma onset, plasticity, and therapeutic response
Noncoding RNA circuitry in melanoma onset, plasticity, and therapeutic response Open
View article: Melanoma clonal subline analysis uncovers heterogeneity-driven immunotherapy resistance mechanisms
Melanoma clonal subline analysis uncovers heterogeneity-driven immunotherapy resistance mechanisms Open
Intratumoral heterogeneity (ITH) can promote cancer progression and treatment failure, but the complexity of the regulatory programs and contextual factors involved complicates its study. To understand the specific contribution of ITH to i…
View article: SERPINB3 induces the basal-like/squamous subtype and enhances disease progression in pancreatic cancer
SERPINB3 induces the basal-like/squamous subtype and enhances disease progression in pancreatic cancer Open
Pancreatic cancer is a heterogeneous disease with distinct subtypes. Here, we investigated candidate driver genes of the highly aggressive basal-like/squamous molecular subtype of pancreatic ductal adenocarcinoma (PDAC). Integrative transc…
View article: Supplementary Table S2 from Ingenuity Network-Assisted Transcription Profiling: Identification of a New Pharmacologic Mechanism for MK886
Supplementary Table S2 from Ingenuity Network-Assisted Transcription Profiling: Identification of a New Pharmacologic Mechanism for MK886 Open
NCI-60 data
View article: Supplementary Data from The Outcome of TGFβ Antagonism in Metastatic Breast Cancer Models <i>In Vivo</i> Reflects a Complex Balance between Tumor-Suppressive and Proprogression Activities of TGFβ
Supplementary Data from The Outcome of TGFβ Antagonism in Metastatic Breast Cancer Models <i>In Vivo</i> Reflects a Complex Balance between Tumor-Suppressive and Proprogression Activities of TGFβ Open
Supplementary Materials and Methods and Supplementary Figures S1-S10
View article: Supplementary Data from The Outcome of TGFβ Antagonism in Metastatic Breast Cancer Models <i>In Vivo</i> Reflects a Complex Balance between Tumor-Suppressive and Proprogression Activities of TGFβ
Supplementary Data from The Outcome of TGFβ Antagonism in Metastatic Breast Cancer Models <i>In Vivo</i> Reflects a Complex Balance between Tumor-Suppressive and Proprogression Activities of TGFβ Open
Supplementary Table S1
View article: Supplementary table 7 from Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer
Supplementary table 7 from Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer Open
Primers used for SV validation experiments
View article: Data from Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer
Data from Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer Open
Gastric cancer and esophageal cancer are the second and sixth leading causes of cancer-related death worldwide. Multiple genomic alterations underlying gastric cancer and esophageal squamous cell carcinoma (ESCC) have been identified, but …
View article: Supplementary Materials from Ingenuity Network-Assisted Transcription Profiling: Identification of a New Pharmacologic Mechanism for MK886
Supplementary Materials from Ingenuity Network-Assisted Transcription Profiling: Identification of a New Pharmacologic Mechanism for MK886 Open
RT-PCR primers, gene sequences, parts of discussion beyond the scope of the paper (167 pages).
View article: Supplementary table 1 from Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer
Supplementary table 1 from Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer Open
Summary of demographic and clinical data for 15 sequenced cancer cases.
View article: Table Legend from Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer
Table Legend from Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer Open
It has legends for the supplementary tables.
View article: Supplementary table 8 from Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer
Supplementary table 8 from Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer Open
Primers used for validating somatic SNVs
View article: Supplementary table 5 from Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer
Supplementary table 5 from Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer Open
Summary of somatic SVs
View article: Supplementary Table S1 from Ingenuity Network-Assisted Transcription Profiling: Identification of a New Pharmacologic Mechanism for MK886
Supplementary Table S1 from Ingenuity Network-Assisted Transcription Profiling: Identification of a New Pharmacologic Mechanism for MK886 Open
Microarray Results
View article: Supplementary table 1 from Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer
Supplementary table 1 from Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer Open
Summary of demographic and clinical data for 15 sequenced cancer cases.
View article: Supplementary table 6 from Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer
Supplementary table 6 from Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer Open
IVA disease analysis report
View article: Supplementary table 5 from Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer
Supplementary table 5 from Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer Open
Summary of somatic SVs
View article: Supplementary table 2 from Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer
Supplementary table 2 from Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer Open
Summary of the WGS mapping data
View article: Data from The Outcome of TGFβ Antagonism in Metastatic Breast Cancer Models <i>In Vivo</i> Reflects a Complex Balance between Tumor-Suppressive and Proprogression Activities of TGFβ
Data from The Outcome of TGFβ Antagonism in Metastatic Breast Cancer Models <i>In Vivo</i> Reflects a Complex Balance between Tumor-Suppressive and Proprogression Activities of TGFβ Open
Purpose:TGFβs are overexpressed in many advanced cancers and promote cancer progression through mechanisms that include suppression of immunosurveillance. Multiple strategies to antagonize the TGFβ pathway are in early-phase oncology trial…
View article: Supplementary table 6 from Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer
Supplementary table 6 from Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer Open
IVA disease analysis report
View article: Supplementary table 8 from Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer
Supplementary table 8 from Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer Open
Primers used for validating somatic SNVs